Dewpoint Therapeutics
Prior to Dewpoint, Aravind trained at the Broad Institute of MIT and Harvard where he held roles of increasing responsibility, most recently as Director, Computational R&D.
Aravind’s research at the Broad Institute focused on technologies for generating large-scale perturbational datasets and their computational analysis. Over the past decade, Aravind’s team has generated several large perturbation datasets by treating cultured human cells with small-molecule and biological agents. These data, coupled with powerful pattern recognition algorithms, are made available in a popular public resource called the Connectivity Map and are routinely used by drug hunters to understand mechanisms of action of small-molecules, functionally annotate disease genes, and inform clinical studies.
This person is not in any teams
This person is not in any offices
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.